Skip to main content

Table 2 Clinical outcomes by the selected studies

From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Authors
(year of publication)
Local ControlDistant progression free survivalOverall SurvivalToxicity
Theelen et al. (2019) [17]NS6.6 months15.9 months12 > G3
Lesueur et al. (2018) [20]64,4% 2 yr2,7 months11,1 months14,4% > G3
Chen et al. (2018) [15]88% 1 yr2.3 months24,7 months16% > G3
Schapira et al. (2017) [21]100% 1 yrN.S.17.6 months0 ≥ G4
Bauml et al. (2019) [19]N.S.19.1 months41.6 months5 > G3
Hubbeling et al. (2018) [22]N.S.N.S.N.S.9 > G3
Verma et al. (2018) [16]N.S.N.S.N.S.25 > G3